Prof Greg Challis is the Monash-Warwick Alliance Professor of Sustainable Chemistry (Chemical and Synthetic Biology) in the Department of Chemistry at the University of Warwick and a Research Professor in the Department of Biochemistry and Molecular Biology at Monash University. In 2020, he co-founded the spinout company ErebaGen, and in 2021 became co-director of the Monash-Warwick Alliance Major Research Initiative in Emerging Superbug Threats and a Chief Investigator in the Australian Research Council Centre of Excellence in Innovations in Peptide and Protein Science. His research interests encompass the discovery, mechanism of action, biosynthesis, bioengineering and evolution of peptides and other bioactive natural products.